References of "Paquot, Nicolas"
     in
Bookmark and Share    
Full Text
Peer Reviewed
See detailDietary inulin supplementation promotes weight loss in obese individuals
Hiel, Sophie; Rodriguez, Julie; Gianfrancesco, Marco ULiege et al

Poster (2017, September)

Detailed reference viewed: 19 (0 ULiège)
Full Text
Peer Reviewed
See detailInfluence of environmental factors on food intake among nursing home residents: a survey combined with a video approach
Buckinx, Fanny ULiege; Reginster, Jean-Yves ULiege; Morelle, Alison et al

in Clinical Interventions in Aging (2017), 12

Background: In addition to the well-known physiological factors, dietary behavior that affects health seems to be influenced by a wide variety of environmental factors. The aim of this study was to assess ... [more ▼]

Background: In addition to the well-known physiological factors, dietary behavior that affects health seems to be influenced by a wide variety of environmental factors. The aim of this study was to assess, by means of an original video approach, the influence of the environment on food intake in nursing homes. Methods: The perception of the environment during meals in nursing homes was evaluated by residents and by two groups of volunteers who either work in the field of geriatrics, or who do not work in the field of geriatrics. First, a random sample of residents answered a self-administered questionnaire related to different indicators (ie, noise, space, comfort, light, odors, perceived satisfaction of meals, taste of meals, presentation of meals, service and setting). Second, two separate panels, one including the people who work in the field of geriatrics (ie, experts) and one including the people who have no particular interest in geriatrics (ie, nonexperts), were asked to answer a questionnaire on their perception of the environment after having watched a video of the lunch in each nursing home. Then, the food intake of the residents was measured by a precise food-weighing method. Results: A total of 88 residents from nine different nursing homes, 18 experts and 45 nonexperts answered the questionnaires. This study highlighted that, on the one hand, after adjustment on confounding variables, the perception of the quantity of food served by the residents is the only single factor associated with food consumption (P=0.003). On the other hand, experts and nonexperts did not perceive any environmental factor that seems to be significantly associated with residents’ food intake. Conclusion: Our results highlighted that, in a nursing home setting, environmental factors have limited influence on the food intake of the residents, with the exception of their own perception of the quantity served. The relevance of this factor deserves further investigation. [less ▲]

Detailed reference viewed: 62 (2 ULiège)
Full Text
Peer Reviewed
See detailInvestigational glucagon receptor antagonists in Phase I and II clinical trials for diabetes.
Scheen, André ULiege; Paquot, Nicolas ULiege; Lefèbvre, Pierre ULiege

in Expert Opinion on Investigational Drugs (2017), 26(12), 1373-1389

INTRODUCTION: Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. However ... [more ▼]

INTRODUCTION: Despite type 2 diabetes (T2D) being recognized as a bihormonal pancreatic disease, current therapies are mainly focusing on insulin, while targeting glucagon has been long dismissed. However, glucagon receptor (GCGr) antagonists are currently investigated in clinical trials. Area covered: Following a brief description of the rationale for antagonizing GCGr in T2D, lessons from GCGr knock-out mice and pharmacological means to antagonize GCGr, a detailed description of the main results obtained with GCGr antagonists in Phase I-II clinical trials is provided. The development of several small molecules has been discontinued, while new ones are currently considered as well as innovative approaches such as monoclonal antibodies or antisense oligonucleotides inhibiting GCGr gene expression. Their potential benefits but also limitations are discussed. Expert opinion: The proof-of-concept that antagonizing GCGr improves glucose control in T2D has been confirmed in humans. Nevertheless, some adverse events led to stopping the development of some of these GCGr antagonists. New approaches seem to have a better benefit/risk balance, although none has progressed to Phase III clinical trials so far. Pharmacotherapy of T2D is becoming a highly competitive field so that GCGr antagonists should provide clear advantages over numerous existing glucose-lowering medications before eventually reaching clinical practice. [less ▲]

Detailed reference viewed: 11 (0 ULiège)
Full Text
Peer Reviewed
See detailVignette therapeutique de l'etudiant. Quel medicament antidiabetique choisir chez un patient diabetique de type 2 avec insuffisance cardiaque ?
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale de Liège (2017), 72(9), 423-428

Heart failure is raising an increasing interest in patients with type 2 diabetes. Indeed, they combine different risk factors for this complication and they have time to develop it because they survive ... [more ▼]

Heart failure is raising an increasing interest in patients with type 2 diabetes. Indeed, they combine different risk factors for this complication and they have time to develop it because they survive longer due to a better prevention of atherothrombotic cardiovascular events. Beyond the classical therapy of heart failure, management should select the most suited glucose-lowering agents. Indeed, all do not have the same impact as some of them have proven their ability to reduce the risk of hospitalisation for heart failure whereas others are associated with an increased risk, either well proven or at least suspected. The aim of this clinical case is to discuss the use of glucose-lowering drugs in a patient with type 2 diabetes with or at risk to develop heart failure. [less ▲]

Detailed reference viewed: 15 (0 ULiège)
Full Text
Peer Reviewed
See detailVignette therapeutique de l'etudiant Comment prescrire un medicament antidiabetique oral chez un patient diabetique de type 2 avec insuffisance renale ?
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale de Liège (2017), 72(10), 462-468

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are increasingly numerous, especially in the elderly population. Surprisingly, this situation is often under-recognized or even ... [more ▼]

Patients with type 2 diabetes (T2D) and chronic kidney disease (CKD) are increasingly numerous, especially in the elderly population. Surprisingly, this situation is often under-recognized or even neglected in clinical practice. Yet, most oral antidiabetic (OAD) agents have limitations in case of renal impairment, either because they require a dose reduction, or are contra-indicated mainly for safety reasons. This clinical case gives the opportunity to discuss the modalities of prescription and cautions to be taken when using most commonly prescribed OAD, metformin, insulin secretagogues (sulfonylureas, repaglinide), DPP-4 inhibitors (gliptins) and SGLT2 inhibitors, in a patient with T2D and CKD. [less ▲]

Detailed reference viewed: 51 (2 ULiège)
Full Text
Peer Reviewed
See detailInhibiteur de la DPP-4 ou des SGLT2 apres echec de la metformine seule dans le diabete de type 2.
Paquot, Nicolas ULiege; Scheen, André ULiege

in Revue Médicale Suisse (2017), 13(571), 1410-1415

After failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporters type 2 (gliflozins) offer an alternative to the add-on of a sulphonylurea ... [more ▼]

After failure of a monotherapy with metformin, dipeptidyl peptidase-4 inhibitors (gliptins) and sodium-glucose cotransporters type 2 (gliflozins) offer an alternative to the add-on of a sulphonylurea, especially in diabetic patients at risk of hypoglycaemia. The choice between a gliptin and a gliflozin may be guided by the individual patient characteristics : rather a gliptin in a patient without obesity or severe hyperglycaemia, in an elderly patient, with a frailty profile or with renal impairment; rather a gliflozin in an obese patient, with hypertension, hyperuricaemia, antecedents of cardiovascular disease (especially heart failure), without advanced renal insufficiency and with a low risk of urinary/genital infections or events linked to dehydration such as hypotension. [less ▲]

Detailed reference viewed: 22 (0 ULiège)
Full Text
Peer Reviewed
See detailOptions therapeutiques chez un patient diabetique de type 2 mal controle par une insuline basale.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2017), 13(571), 1416-1420

In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes ... [more ▼]

In a patient with type 2 diabetes not well controlled with a basal insulin - metformin combination, several therapeutic options may be considered: intensifying insulin therapy with different schemes (appropriate titration using a more favourable basal insulin analogue, adding one, two or three rapid-acting insulin analogues, shift to two or three premix insulin injections), adding a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of sodium-glucose cotransporters type 2 (gliflozin), or combining a glucagon-like peptide-1 receptor agonist with basal insulin. The choice should be made according the individual profile and preference of the patient, in a personalized approach, taking into account the advantages and disadvantages of each therapeutic solution. [less ▲]

Detailed reference viewed: 20 (0 ULiège)
Full Text
Peer Reviewed
See detailEnergy and nutrient content of food served and consumed by nursing home residents
Buckinx, Fanny ULiege; ALLEPAERTS, Sophie ULiege; PAQUOT, Nicolas ULiege et al

in the journal of nutrition, health & aging (2017), 21(6), 727-32

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food ... [more ▼]

Objective: The aim of this study was to compare energy and protein content of the served food with the actual intake from the food consumed by nursing home residents. This study also aimed to compare food intake and dietary allowances. Design: This is a cross sectional study. Setting: This study was performed in nursing homes. Participants: Residents of these 2 nursing homes were eligible for the study if they agreed to participate and if they meet the selection criteria (to be older than 65 years and have a regular texture diet). Measurement: Nutrient content of the served food and real food consumption was calculated for all meals during a 5-day period by precise weighting method. Difference between consumed and served dietary content was evaluated by the Chi² test. Results: Seventy-four Belgian nursing home residents (75% of women, 85.8 ± 7.04 years on average) were included in this study. These subjects had a mean body mass index of 24.9 ± 4.83 kg/m². The mean energy content of the served food was 1783.3 ± 125.7 kcal per day. However, residents did not eat the whole of the meals and the actual energy content of the consumed food was significantly less (1552.4 ± 342.1 kcal per day; p<.001). The average protein content of the food served was equal to 0.96 ± 0.20 g/kg/day and the average consumption of protein by the residents was 0.88 ± 0.25 g/kg/day. The difference between protein served and consumed was also significant (p=.04). Moreover, people considered as well nourished, eating significantly more energy than the others (p=.04). Conclusion: Meals served in nursing homes are not entirely consumed by their residents. As expected, the energy consumed are lower in subjects considered as malnourished or at risk of malnutrition. [less ▲]

Detailed reference viewed: 31 (10 ULiège)
Full Text
Peer Reviewed
See detailVignette therapeutique de l'etudiant. Optimisation d'un traitement par insuline basale chez le patient diabetique de type 2.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale de Liège (2017), 72(3), 156-161

Because of the natural history of type 2 diabetes and the increasing life expectancy, more and more patients are treated with insulin after failure of oral therapy. International guidelines give the ... [more ▼]

Because of the natural history of type 2 diabetes and the increasing life expectancy, more and more patients are treated with insulin after failure of oral therapy. International guidelines give the preference to basal insulin, most often while maintaining metformin. If this treatment does not allow to reach the glycaemic objectives, optimizing therapy is mandatory. This clinical case offers the opportunity of discussing both advantages and disadvantages of three therapeutic options : the shift from basal insulin to a basal-plus or a basal-bolus insulin regimen, the addition of another oral glucose-lowering agent, either a dipeptidyl peptidase-4 inhibitor (gliptin) or an inhibitor of cotransporters sodium-glucose type 2 cotransporters (gliflozin), or the combination of basal insulin and a glucagon-like peptide-1 receptor agonist. [less ▲]

Detailed reference viewed: 37 (2 ULiège)
Full Text
Peer Reviewed
See detailLa vignette thérapeutique de l'étudiant. Le choix entre un inhibiteur de la DPP-4 et un inhibiteur des SGLT2 pour traiter le diabète de type 2 (2016)
SCHEEN, André ULiege; PAQUOT, Nicolas ULiege

in Revue Médicale de Liège (2016), 71(12), 579-585

Summary : Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters ... [more ▼]

Summary : Two new classes of oral antidiabetic agents play an increasing role in the management of type 2 diabetes, dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) and sodiumglucose cotransporters type 2 (SGLT2) inhibitors (gliflozins). After failure of a monotherapy with metformin (first pharmacological choice in type 2 diabetes), both may offer an alternative to the add-on of a sulphonylurea, especially in patients at risk of hypoglycaemia. However, the choice between a DPP-4 inhibitor and a SGLT2 inhibitor is not easy and should be oriented based upon the individual patient characteristics. The arguments in favour of one or another pharmacological class are discussed, considering a clinical case of a patient with coronary heart disease and type 2 diabetes not well controlled with metformin. [less ▲]

Detailed reference viewed: 46 (3 ULiège)
Full Text
See detailNos patients cancéreux sont-ils déjà cachectiques lors de la première évéluation nutritionnelle ?
MALHERBE, Christian ULiege; VERBRUGGE, Anne-Marie ULiege; DE FLINES, Jenny ULiege et al

Conference (2016, December)

we want to know if, during the first nutritional evaluation, our cancer patients are already cachectic or no. <in order to improve our institutional practices

Detailed reference viewed: 15 (0 ULiège)
See detailInvolvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages
Gianfrancesco, Marco ULiege; Dehairs, Jonas; Bloch, Katerzina et al

Poster (2016, September 12)

Detailed reference viewed: 32 (3 ULiège)
Full Text
Peer Reviewed
See detailLa vignette diagnostique de l’étudiant Mise au point d’une suspicion de malaise hypoglycémique chez une personne adulte non diabétique
SCHEEN, André ULiege; PAQUOT, Nicolas ULiege; LEFEBVRE, Pierre ULiege

in Revue Médicale de Liège (2016), 71(09), 407-413

Résumé : La survenue de malaises est souvent attribuée à une hypoglycémie chez des personnes non diabétiques et, a priori, sans autre problème de santé. Ce diagnostic est, cependant, souvent galvaudé, car ... [more ▼]

Résumé : La survenue de malaises est souvent attribuée à une hypoglycémie chez des personnes non diabétiques et, a priori, sans autre problème de santé. Ce diagnostic est, cependant, souvent galvaudé, car habituellement non clairement démontré. Le diagnostic d’hypoglycémie doit se faire de façon structurée en se basant sur la triade de Whipple. Tout d’abord, l’anamnèse doit rechercher les symptômes évocateurs d’hypoglycémie, adrénergiques et neuroglucopéniques. Ensuite, l’hypoglycémie doit être authentifiée par une mesure d’une valeur basse au moment d’un malaise. Enfin, s’il s’agit bien d’une hypoglycémie, le malaise doit disparaître rapidement après resucrage. Une fois le diagnostic posé sur la base de cette triade, l’anamnèse doit faire préciser, outre la sévérité des malaises, leur chronologie, après les repas ou à jeun, ce qui oriente vers une hypoglycémie réactive, fonctionnelle, ou vers une hypoglycémie d’origine organique (insulinome). Des examens complémentaires, faisant d’abord appel à la biologie clinique, ensuite éventuellement à l’imagerie médicale, permettront de, non seulement confirmer le diagnostic d’hypoglycémie, mais aussi d’en préciser l’origine, ce qui orientera la stratégie thérapeutique. [less ▲]

Detailed reference viewed: 37 (6 ULiège)
Full Text
Peer Reviewed
See detailProtection cardiovasculaire et rénale du patient diabétique de type 2 : le point après EMPA-REG OUTCOME et LEADER
SCHEEN, André ULiege; PIERARD, Luc ULiege; KRZESINSKI, Jean-Marie ULiege et al

in Revue Médicale de Liège (2016), 71(09), 376-381

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a ... [more ▼]

Summary : Type 2 diabetes (T2D), often associated with arterial hypertension, represents a high risk of cardiovascular disease and nephropathy. Two clinical trials demonstrate the superiority versus a placebo of two antidiabetic drugs in patients with T2D and high cardiovascular risk : empagliflozin, an inhibitor of sodium-glucose type 2 (SGLT2) cotransporters, in EMPA-REG OUTCOME and liraglutide, an agonist of glucagon-like peptide-1 (GLP-1) receptors, in LEADER. Both medications showed a significant reduction in major cardiovascular events (-14 and -13 %, respectively), cardiovascular mortality (-38 and -22%), all-cause mortality (-32 and -15 %) and renal events (-39 et -22 %). The underlying protective mechanisms remain controverted. Ongoing studies should allow to decide whether the benefits are specific to each molecule or may be attributed to a class effect. [less ▲]

Detailed reference viewed: 60 (1 ULiège)
Full Text
Peer Reviewed
See detailInvolvement of membrane remodelling induced by fatty acids in the regulation of the NLRP3 inflammasome activity in human macrophages
Gianfrancesco, Marco ULiege; Dehairs, Jonas; Bloch, Katarzyna et al

in Diabetologia (2016, August), 59(Supplement 1), 291

Detailed reference viewed: 35 (9 ULiège)
Full Text
See detailLes bienfaits du sport sur la santé de la personne diabétique
PAQUOT, Nicolas ULiege

in Revue de l'ABD (2016)

Detailed reference viewed: 58 (4 ULiège)
See detailLe diabète et la sélection médicale
PAQUOT, Nicolas ULiege

Conference (2016, April 27)

Detailed reference viewed: 25 (1 ULiège)
Full Text
Peer Reviewed
See detailCombinaison gliptine-gliflozine dans le traitement du diabete de type 2.
Scheen, André ULiege; Paquot, Nicolas ULiege

in Revue Médicale Suisse (2016), 12(527), 1384-1388

Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 ... [more ▼]

Type 2 diabetes (T2D) is a complex disease with multiple defects, which generally require a combination of several pharmacological approaches to control hyperglycaemia. Combining a dipeptidyl peptidase-4 inhibitor (DPP-4i) and a sodium-glucose cotransporter type 2 inhibitor (SGT2i) appears to be an attractive approach because the two drugs exert different and potentially complementary glucose-lowering effects. Dual therapy (initial combination or stepwise approach) is more potent than either monotherapy in patients treated with diet and exercise or already treated with metformin. Combining the two pharmacological options is safe and does not induce hypoglycaemia. Two fixed-dose combinations (FDCs) are already available (saxagliptin-dapagliflozin and linagliptin-empagliflozin) and others are in current development. [less ▲]

Detailed reference viewed: 67 (2 ULiège)